BURLINGTON, Mass. and JERUSALEM, July 20, 2026 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive brain stimulation technologies, today announced a $3 million minority equity investment in Radial Health, Inc. (“Radial”), a management services organization supporting a leading network of Brain Medicine clinics across the country.

马萨诸塞州伯灵顿和耶路撒冷，2026年7月20日（环球电讯社）——全球先进无创脑刺激技术领导者BrainsWay Ltd.（纳斯达克及特拉维夫证券交易所：BWAY）（“BrainsWay”或“公司”）今日宣布，向Radial Health, Inc.（“Radial”）进行300万美元的少数股权投资。Radial是一家管理服务机构，支持遍布全国的领先脑医学诊所网络。

The investment was made as part of Radial's previously-announced Series A financing, and BrainsWay joins other leading investors in Radial, including General Catalyst, Floating Point Capital, Solari Capital, JSL Health Capital, Founder Collective, BoxGroup, Scrub Capital, and Diede van Lamoen..

此次投资是Radial此前宣布的A轮融资的一部分，BrainsWay加入了Radial的其他领先投资者行列，包括General Catalyst、Floating Point Capital、Solari Capital、JSL Health Capital、Founder Collective、BoxGroup、Scrub Capital以及Diede van Lamoen。

Radial specializes in the development of the clinical infrastructure, reimbursement tools, and AI-guided decision support platform designed to support the delivery of “Brain Medicine” treatments, non-invasive therapies like Deep TMS™ and other solutions. The financing is expected to support Radial’s exploration of various M&A opportunities..

Radial 专注于开发临床基础设施、报销工具以及人工智能引导的决策支持平台，旨在支持“脑医学”治疗（如深部经颅磁刺激™等非侵入性疗法）及其他解决方案的交付。此次融资预计将支持 Radial 探索各种并购机会。

“We are pleased to announce our strategic minority investment in Radial, a mental health services provider that is expanding access to advanced psychiatric care,” said Hadar Levy, BrainsWay’s Chief Executive Officer. “This investment in Radial represents the continued execution of our strategic initiative to secure minority equity positions in high performing mental health provider networks that can help expand awareness of and broaden access to noninvasive mental health treatment.”.

BrainsWay首席执行官哈达尔·莱维表示：“我们很高兴宣布，我们对Radial进行了战略性少数股权投资。Radial是一家精神健康服务提供商，正致力于扩大先进精神病治疗的覆盖范围。”“对Radial的这项投资，体现了我们持续执行战略举措，即在表现优异的精神健康提供商网络中获取少数股权，以帮助提高人们对非侵入性精神健康治疗的认知并扩大其可及性。”

“This financing represents an important step forward for Radial as we continue building a national platform for advanced mental health care,” said John Capecelatro, CEO and co-founder of Radial. “We are grateful for the support of BrainsWay and our broader syndicate of investors as we use this capital to expand our clinical footprint, strengthen our technology platform and increase access to innovative, evidence-based Brain Medicine treatment options for patients.”.

“此次融资标志着Radial在构建全国性先进心理健康护理平台方面迈出了重要一步，”Radial首席执行官兼联合创始人John Capecelatro表示。“我们感谢BrainsWay以及更广泛的投资人财团的支持，我们将利用这笔资金扩大临床服务覆盖范围，强化技术平台，并为患者提供更多基于实证的创新脑医学治疗选择。”

Advocates Ami Hordes and Sarit Molcho of S. Friedman, Abramson & Co. Law Offices served as lead counsel for BrainsWay on the transaction as well as on the Company’s prior minority stake investments.

S. Friedman, Abramson & Co. 律师事务所的 Ami Hordes 和 Sarit Molcho 作为 BrainsWay 在此次交易以及公司此前少数股权投资中的首席法律顾问。

About BrainsWay

关于 BrainsWay

BrainsWay is a global leader in advanced noninvasive neurostimulation treatments for mental health disorders. The Company is boldly advancing neuroscience with its proprietary Deep Transcranial Magnetic Stimulation (Deep TMS™) platform technology to improve health and transform lives. BrainsWay is the first and only TMS company to obtain three FDA-cleared indications backed by pivotal clinical studies demonstrating clinically proven efficacy.

BrainsWay 是用于治疗精神健康障碍的先进无创神经刺激疗法的全球领导者。公司凭借其专有的深部经颅磁刺激（Deep TMS™）平台技术，大胆推动神经科学发展，以改善健康并改变生命。BrainsWay 是唯一一家获得三项美国食品药品监督管理局（FDA） cleared 适应症的 TMS 公司，这些适应症均有关键性临床研究支持，证明了其临床疗效。

Current indications include major depressive disorder (including reduction of anxiety symptoms, commonly referred to as anxious depression), obsessive-compulsive disorder, and smoking addiction. The Company is dedicated to leading through superior science and building on its unparalleled body of clinical evidence.

目前的适应症包括重度抑郁症（包括减轻焦虑症状，通常称为焦虑性抑郁）、强迫症和吸烟成瘾。本公司致力于通过卓越的科学引领行业，并以其无与伦比的临床证据体系为基础不断发展。

Additional clinical trials of Deep TMS in various psychiatric, neurological, and addiction disorders are underway. Founded in 2003, with operations in the United States and Israel, BrainsWay is committed to increasing global awareness of and broad access to Deep TMS. For the latest news and information about BrainsWay, please visit .

深部经颅磁刺激（Deep TMS）在各类精神疾病、神经系统疾病及成瘾障碍中的更多临床试验正在进行中。BrainsWay 成立于 2003 年，在美国和以色列开展业务，致力于提高全球对深部经颅磁刺激的认知并扩大其可及性。如需了解关于 BrainsWay 的最新新闻和信息，请访问。

www.brainsway.com

www.brainsway.com

.

。

Forward-Looking Statements

前瞻性陈述

This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements may be preceded by the words “intends,” “may,” “will,” “plans,” “expects,” “anticipates,” “projects,” “predicts,” “estimates,” “aims,” “believes,” “hopes,” “potential” or similar words, and also includes any financial guidance and projections contained herein.

本新闻稿包含1995年《私人证券诉讼改革法案》所指的“前瞻性陈述”。此类陈述可能以“打算”、“可能”、“将”、“计划”、“预期”、“预计”、“规划”、“预测”、“估计”、“旨在”、“相信”、“希望”、“潜在”或类似词语为前缀，还包括本文中包含的任何财务指引和预测。

These forward-looking statements and their implications are based on the current expectations of the management of the Company only and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. In addition, historical results or conclusions from scientific research and clinical studies do not guarantee that future results would suggest similar conclusions or that historical results referred to herein would be interpreted similarly in light of additional research or otherwise.

这些前瞻性陈述及其影响仅基于本公司管理层的当前预期，并受多种因素和不确定性的影响，可能导致实际结果与前瞻性陈述中描述的结果存在重大差异。此外，历史结果或科学研究及临床试验得出的结论并不保证未来结果会得出类似结论，也不保证在额外研究或其他情况下，本文所指的历史结果会以相同方式被解读。

The following factors, among others, could cause actual results to differ materially from those described in the forward-looking statements: risks relating to the Company’s ability to consummate, finance and close proposed or potential investments, inadequacy of financial resources to meet future capital requirements; changes in technology and market requirements; delays or obstacles in launching and/or successfully completing planned studies and clinical trials; failure to obtain approvals by regulatory agencies on the Company’s anticipated timeframe, or at all; inability to retain or attract key employees whose knowledge is essential to the development of Deep TMS products; unforeseen difficulties with Deep TMS products and processes, and/or inability to develop necessary enhancements; unexpe.

除其他因素外，以下因素可能导致实际结果与前瞻性陈述中描述的结果存在重大差异：与公司完成、融资和关闭拟议或潜在投资的能力相关的风险；财务资源不足以满足未来资本需求；技术和市场需求的变化；启动和/或成功完成计划中的研究和临床试验的延迟或障碍；未能在公司预期的时间框架内或根本无法获得监管机构的批准；无法保留或吸引对深部经颅磁刺激（Deep TMS）产品开发至关重要的关键员工；深部经颅磁刺激产品和流程出现不可预见的困难，和/或无法开发必要的增强功能；未预见的。

Any forward-looking statement in this press release speaks only as of the date of this press release. The Company undertakes no obligation to publicly update or review any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by any applicable securities laws.

本新闻稿中的任何前瞻性陈述仅截至本新闻稿发布之日有效。除非适用法律要求，公司没有义务公开更新或审查任何前瞻性陈述，无论是否因新信息、未来发展或其他原因。

More detailed information about the risks and uncertainties affecting the Company is contained under the heading “Risk Factors” in the Company’s filings with the U.S. Securities and Exchange Commission..

有关影响本公司的风险与不确定性的更详细信息，请参阅本公司向美国证券交易委员会提交的文件中“风险因素”一节。

Contacts:

联系人：

BrainsWay:

BrainsWay:

Ido Marom

伊多·马罗姆

Chief Financial Officer

首席财务官

Ido.Marom@BrainsWay.com

Ido.Marom@BrainsWay.com

Investors:

投资者：

Jeff Warren

杰夫·沃伦

LifeSci Advisors LLC

LifeSci 顾问有限责任公司

jwarren@lifesciadvisors.com

jwarren@lifesciadvisors.com